Sana Biotechnology, Inc. Form 8-K Summary
Business Context and Reporting Period
Sana Biotechnology, Inc. filed this Form 8-K on June 9, 2023, reporting the results of its annual meeting of stockholders held on June 8, 2023. The filing covers corporate governance matters under Item 5.07 and does not report quarterly or annual financial results.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating and financial metrics.
Material Changes and Voting Results
- Class II director elections: Hans E. Bishop, Robert Nelsen, and Alise S. Reicin, M.D. were each elected to three-year terms expiring at the 2026 annual meeting or until their successors are elected and qualified.
- Hans E. Bishop: 108,928,064 votes for, 19,856,165 withheld, and 14,296,363 broker non-votes.
- Robert Nelsen: 111,403,976 votes for, 17,380,253 withheld, and 14,296,363 broker non-votes.
- Alise S. Reicin, M.D.: 110,664,981 votes for, 18,119,248 withheld, and 14,296,363 broker non-votes.
- Auditor ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, with 142,770,600 votes for, 184,749 against, and 125,243 abstentions.
Guidance, Outlook, Risks, and Unusual Items
The filing contains no financial guidance, business outlook, management commentary, risk updates, contingencies, or unusual accounting items. It confirms only the director elections and auditor ratification described above.
Key Facts to Verify
- Confirm the elected Class II directors’ terms and subsequent board composition.
- Confirm Ernst & Young LLP’s continued appointment for the fiscal year ending December 31, 2023.
- Review the definitive proxy statement filed April 28, 2023 for the detailed proposal descriptions and voting standards.
- Obtain the Company’s periodic financial filings separately, because this Form 8-K provides no financial performance or liquidity information.